Literature DB >> 10343058

Comparison of the abilities of Salmonella typhimurium rpoS, aroA and rpoS aroA strains to elicit humoral immune responses in BALB/c mice and to cause lethal infection in athymic BALB/c mice.

C Coynault1, F Norel.   

Abstract

Salmonella typhimurium rpoS and rpoS aroA mutants are effective live vaccines in the murine model of salmonellosis (Coynault et al., Mol. Microbiol. 1996; 22: 149-60). Here, we further investigate the characteristics of these vaccines. The systemic humoral response induced by S. typhimurium rpoS, aroA and rpoS aroA vaccine candidates against S. typhimurium LPS was studied by ELISA. In BALB/c mice, the rpoS aroA strain induced a systemic anti-LPS humoral response similar to that induced by the rpoS and aroA strains. The virulence of aroA and rpoS aroA vaccines in nude (nu/nu) BALB/c mice was also compared. Salmonella typhimurium aroA and rpoS aroA vaccines both produced slowly progressing lethal infections in athymic mice inoculated i.p. but the rpoS aroA strain was more attenuated than the aroA strain, as determined by time to death and bacterial counts in spleens. Finally, a rpoS mutant of Salmonella dublin conferred protection in mice against an oral challenge with a wild-type strain of S. dublin whereas a rpoS mutant of S. typhimurium did not. This suggests that the protection provided by the S. typhimurium rpoS vaccine is serotype-dependent. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10343058     DOI: 10.1006/mpat.1999.0273

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  10 in total

Review 1.  Problems posed by natural environments for monitoring microorganisms.

Authors:  C Edwards
Journal:  Mol Biotechnol       Date:  2000-07       Impact factor: 2.695

Review 2.  Bacterial infectious disease control by vaccine development.

Authors:  Roy Curtiss
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 3.  Microbial responses to microgravity and other low-shear environments.

Authors:  Cheryl A Nickerson; C Mark Ott; James W Wilson; Rajee Ramamurthy; Duane L Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

Review 4.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

5.  Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in Salmonella enterica serotype Typhi.

Authors:  Javier Santander; Soo-Young Wanda; Cheryl A Nickerson; Roy Curtiss
Journal:  Infect Immun       Date:  2006-12-18       Impact factor: 3.441

Review 6.  Role of RpoS in virulence of pathogens.

Authors:  Tao Dong; Herb E Schellhorn
Journal:  Infect Immun       Date:  2009-11-30       Impact factor: 3.441

7.  Identification of RpoS (sigma(S))-regulated genes in Salmonella enterica serovar typhimurium.

Authors:  M Ibanez-Ruiz; V Robbe-Saule; D Hermant; S Labrude; F Norel
Journal:  J Bacteriol       Date:  2000-10       Impact factor: 3.490

8.  Immunological responses against Salmonella enterica serovar Typhimurium Braun lipoprotein and lipid A mutant strains in Swiss-Webster mice: potential use as live-attenuated vaccines.

Authors:  Tie Liu; Rolf König; Jian Sha; Stacy L Agar; Chien-Te K Tseng; Gary R Klimpel; Ashok K Chopra
Journal:  Microb Pathog       Date:  2007-10-06       Impact factor: 3.738

9.  Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen.

Authors:  Huoying Shi; Javier Santander; Karen E Brenneman; Soo-Young Wanda; Shifeng Wang; Patti Senechal; Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  PLoS One       Date:  2010-06-18       Impact factor: 3.240

10.  Regulation of Vi capsular polysaccharide synthesis in Salmonella enterica serotype Typhi.

Authors:  Javier Santander; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2008-12-01       Impact factor: 0.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.